Jeffrey S. Weber, MD, PhD, shares toxicity data from the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.
Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, shares toxicity data from the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.
The toxicity data have not been updated since the presentation on the trial at the 2017 ESMO Congress, which included all patients who were followed up to 100 days after treatment, says Weber.
At the meeting, Weber reported that 8% of patients in the nivolumab (Opdivo) arm had to stop treatment due to toxicity. Furthermore, around 10% to 15% of patients experienced grade 3 or 4 immune-related adverse events that were determined to be of significance. The data, according to Weber, were in line with what would be seen in the metastatic setting when single-agent PD-1 drugs like nivolumab or pembrolizumab (Keytruda) are used, Weber concludes.